




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D

* Indicates values significantly greater than treatment with either agent alone $p < 0.01$

3/10







FIG. 2

Cells and treatment	% of cells		
	G0/G1	S	G2/M
<u>K-562</u>			
Untreated	42.6 ± 0.1	35.4 ± 1.6	22.1 ± 1.7
10 nM BC2059	45.5 ± 0.6	33.4 ± 0.6	21.1 ± 0.8
20 nM BC2059	45.8 ± 1.4	34.7 ± 1.3	19.6 ± 0.9
50 nM BC2059	49.2 ± 1.4	28.2 ± 0.9	22.5 ± 1.3

FIG. 3A

Cells and treatment	% of cells		
	G0/G1	S	G2/M
<u>LAMA-84</u>			
Untreated	43.9 ± 4.8	41.8 ± 4.5	14.3 ± 0.3
10 nM BC2059	42.0 ± 5.1	43.7 ± 6.1	14.3 ± 1.3
20 nM BC2059	48.5 ± 4.6	37.9 ± 5.1	13.5 ± 1.3
50 nM BC2059	52.5 ± 0.8	34.5 ± 0.5	13.0 ± 0.9

FIG. 3B



*Indicates values significantly greater than treatment with either agent alone $p < 0.01$




FIG. 5A

CD34+ FLT3-ITD Primary AML cells




FIG. 5B




FIG. 7C





FIG. 6C




FIG. 7A




FIG. 7B




FIG. 7C

9/10




FIG. 8A




FIG. 8B

10/10




FIG. 8C




FIG. 8D